ORIC Pharmaceuticals (ORIC): H.C. Wainwright Sees 111% Upside Potential Following Phase 1b Data for ORIC-944

Last year, the biotechnology sector sparked hopes for a wave of M&A activity. Leading companies such as AstraZeneca, AbbVie, Johnson & Johnson, and Merck strategically acquired smaller firms to expand their portfolios. Focus areas included oncology, immunology, and cardiovascular medicine. Notably, AstraZeneca's acquisition of Fusion Pharmaceuticals for $2.4 billion and Johnson & Johnson's purchase of Shockwave Medical for $13.1 billion stood out. These acquisitions aim to drive innovation and secure market shares. In the still young trading...